Related Experiment Video
Updated: Jul 18, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Clinical and Epidemiological Findings of Pediatric Onset Multiple Sclerosis in East-Azerbaijan, Iran; A
Ehsan Nasiri1,2, Amirreza Naseri1,2, Mahnaz Talebi2
1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Insights
Pediatric-onset multiple sclerosis (POMS) affects 2.85% of MS cases, predominantly females, with prevalence increasing after age 15. Blurred vision is the most common initial symptom in POMS patients.
Area of Science:
- Neurology
- Epidemiology
- Immunology
Background:
- Multiple sclerosis (MS) is a chronic immune-mediated inflammatory disease.
- Pediatric-onset MS (POMS) is defined as MS with onset before age 18.
- Understanding POMS clinical and epidemiological aspects is crucial for early diagnosis and management.
Purpose of the Study:
- To determine the clinical and epidemiological characteristics of POMS in East-Azerbaijan province.
- To establish the prevalence and incidence of POMS in the studied region.
- To identify common presenting symptoms and demographic factors in POMS.
Main Methods:
- A population-based study utilizing data from the sole MS registry center in East-Azerbaijan province.
- Inclusion of POMS patients diagnosed by McDonald's criteria by the end of 2017.
- Data collection focused on demographic information, age of onset, family history, diagnostic delay, and initial clinical presentations.
Main Results:
- POMS accounted for 2.85% of all MS cases (85 out of 2976).
- The regional prevalence of POMS was 11.67 per 100,000, with a significantly higher prevalence in females (18.94 per 100,000) compared to males (4.80 per 100,000).
- The mean age of onset was 15.81 years, with 71.76% diagnosed between 16-17 years old. Blurred vision was the most frequent initial symptom (43.75%).
Conclusions:
- Pediatric-onset MS is not rare and predominantly affects females.
- POMS prevalence rises notably after age 15.
- Blurred vision is the typical first clinical manifestation of POMS.
Objectives:
Multiple sclerosis (MS) is among the most prevalent chronic immune-mediated inflammatory diseases. If MS onset is under 18, it is defined as pediatric-onset MS (POMS). This study aimed to determine the clinical and epidemiological aspects of POMS.
Materials & Methods:
This population-based study was conducted in East-Azerbaijan (EA) province and concerned POMS patients. The data concerning almost all of the POMS patients of the province was gathered from the only MS registry center in the university hospital of the Tabriz University of Medical Sciences by the end of 2017. The diagnosis of patients was based on McDonald's criteria.
Results:
Out of 2976 total cases of MS, eighty-five (2.85%) were POMS. The overall regional prevalence of POMS was 11.67 per 100,000 (95% CI:9.43-11.43). Sixty-seven cases were female (prevalence: 18.94 per 100,000 [95% CI:14.91-24.07], and eighteen were male (prevalence: 4.80 per 100,000 [95% CI:3.03-7.62]. The crude regional incidence in 2017 was 1.37/100,000 (95% CI:0.74-2.55). The mean age of onset was 15.81±1.33 years, with a minimum age of 12. 71.76% of the patients were diagnosed in the 16- or 17-years old age group. 7.05% had a positive family history, and 87.5% of the patients diagnosed the disease promptly. The most common first clinical presentations were blurred vision (43.75%), sensory (28.12%), cerebellar (15.62%), and brainstem (9.37%) symptoms.
Conclusion:
POMS is not a rare condition, and it mainly affects females. POMS prevalence increases significantly after age 15 years old, and the first manifestation of the disease is usually blurred vision.
More Related Videos
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Bias in Epidemiological Studies
Psychological and Sociocultural Causes of Schizophrenia
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

